CTOs on the Move

OpenTrons

www.opentrons.com

 
We make robots for biologists. Our mission is to provide the scientific community with a common platform to easily share protocols and reproduce each other`s results. Our robots automate experiments that would otherwise be done by hand, allowing our community to spend more time pursuing answers to some of the 21st century`s most important questions.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.opentrons.com
  • 45-18 Court Square West
    Long Island City, NY USA 11101
  • Phone: 857.577.7656

Executives

Name Title Contact Details

Funding

OpenTrons raised $10M on 03/27/2018

Similar Companies

Access Genetics LLC

Access Genetics LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Modis Therapeutics

Modis Therapeutics is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need.

Perimeter Resources

Perimeter Resources is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Turn Biotechnologies

Turn Biotechnologies develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. We are focused on reprogramming the epigenome – a network of chemical compounds and proteins that control cell functions by influencing which genes are active – to restore capabilities that are often lost with age.

Celularity

Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity`s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature`s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases.